L-Ascorbic acid sodium salt is a more bioavailable form of vitamin C that is an antioxidant agent.

L-Ascorbic acid sodium salt, a known enhancer of collagen deposition, has also been identified as an inhibitor of elastogenesis[1]. The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by sodium L-ascorbate (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000[2].

Tg rats treated with sodium L-ascorbate show a higher incidence of carcinoma (29.6%), compared to those without sodium L-ascorbate (15.4%). Independent of the sodium L-ascorbate treatment, transgenic rats exhibit various kinds of malignant tumors in various organs[3]. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the sodium L-ascorbate-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the sodium L-ascorbate-treatment is evident only with simple hyperplasias and PN hyperplasias in rats[4].